NEW YORK, NY / ACCESSWIRE / June 1, 2018 / U.S. markets closed sharply lower on Thursday as the U.S. decided to impose tariffs on steel and aluminum imports from Canada, Mexico and the European Union. The tariffs incited promises of retaliation by trade partners and raised fears of a potential trade war. The Dow Jones Industrial Average dropped 1.02 percent to close at 24,415.84, while the S&P 500 Index declined 0.69 percent to close at 2,705.27. The Nasdaq Composite Index was down 0.27 percent to close at 7,442.12.

"The initial round of tariff threats by the Trump administration and the promises of retaliation by trade partners earlier this year were initially viewed by investors as opening gambits in negotiations that would lead to agreements," said Art Hogan, chief market strategist at B. Riley FBR.

RDI Initiates Coverage on:

Tesaro, Inc.
https://rdinvesting.com/news/?ticker=TSRO

Agios Pharmaceuticals, Inc.
https://rdinvesting.com/news/?ticker=AGIO

Tesaro's stock moved 2.95% higher Thursday, to close the day at $45.77. The stock recorded a trading volume of 5,007,900 shares, which was above its three months average volume of 1,234,157 shares. In the last year, Tesaro's shares have traded in a range of 42.81 - 153.98. The share price has gained 6.91% from its 52 week low. The company's shares are currently trading below their 200-day moving average. The stock's 50-day moving average of $50.05 is below its 200-day moving average of $64.67. Shares of Tesaro have fallen roughly 10.10 percent in the past month and are down 44.77 percent year-to-date.

Access RDI's Tesaro, Inc. Research Report at:
https://rdinvesting.com/news/?ticker=TSRO

On Thursday, shares of Agios Pharmaceuticals recorded a trading volume of 584,682 shares, which was above the three months average volume of 374,573 shares. The stock ended the day 3.58% higher at $93.50. The share price has fallen 1.48% from its 52 week high with a 52 week trading range of 47.25 - 94.90. The company's shares are currently trading above their 200-day moving average. The stock's 50-day moving average of $86.06 is above its 200-day moving average of $75.06. Shares of Agios Pharmaceuticals have gained roughly 11.43 percent in the past month and are up 63.55 percent year-to-date.

Access RDI's Agios Pharmaceuticals, Inc. Research Report at:
https://rdinvesting.com/news/?ticker=AGIO

Our Actionable Research on Tesaro, Inc. (NASDAQ:TSRO) and Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) can be downloaded free of charge at Research Driven Investing.

Research Driven Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker-dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com